Analysts See 25% Upside For The Holdings of IHE

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares U.S. Pharmaceuticals ETF (IHE), we found that the implied analyst target price for the ETF based upon its underlying holdings is $181.62 per unit.

START SLIDESHOW:
10 ETFs With Most Upside To Analyst Targets »

With IHE trading at a recent price near $145.17 per unit, that means that analysts see 25.11% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of IHE's underlying holdings with notable upside to their analyst target prices are TherapeuticsMD, Inc. ( TXMD), Revance Therapeutics Inc ( RVNC), and Intra-Cellular Therapies Inc ( ITCI). Although TXMD has traded at a recent price of $6.96/share, the average analyst target is 124.50% higher at $15.62/share. Similarly, RVNC has 97.55% upside from the recent share price of $18.35 if the average analyst target price of $36.25/share is reached, and analysts on average are expecting ITCI to reach a target price of $26.25/share, which is 94.16% above the recent price of $13.52. Below is a twelve month price history chart comparing the stock performance of TXMD, RVNC, and ITCI:

TXMD, RVNC, and ITCI Relative Performance Chart

Below is a summary table of the current analyst target prices discussed above:

Name Symbol Recent Price Avg. Analyst 12-Mo. Target % Upside to Target
iShares U.S. Pharmaceuticals ETF IHE $145.17 $181.62 25.11%
TherapeuticsMD, Inc. TXMD $6.96 $15.62 124.50%
Revance Therapeutics Inc RVNC $18.35 $36.25 97.55%
Intra-Cellular Therapies Inc ITCI $13.52 $26.25 94.16%

Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.

More from Stocks

Never Buy Stocks Based on Unusual Call Activity: Doug Kass Insider

Never Buy Stocks Based on Unusual Call Activity: Doug Kass Insider

Will Tesla Stock Tumble 33% to $195?

Will Tesla Stock Tumble 33% to $195?

Is Best Buy Sleeping With the Enemy With Amazon Partnership?

Is Best Buy Sleeping With the Enemy With Amazon Partnership?

Video: The S&P 500 Is Failing to Make New Highs

Video: The S&P 500 Is Failing to Make New Highs

Dow, S&P 500 and Nasdaq Finish Lower as Apple, P&G Slump

Dow, S&P 500 and Nasdaq Finish Lower as Apple, P&G Slump